ELACESTRANT MONOTHERAPY VS. STANDARD OF CARE FOR
THE TREATMENT OF PATIENTS WITH ER+/HER2- ADVANCED BREAST
CANCER FOLLOWING CDK4/6 INHIBITOR THERAPY: A PHASE 3 RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER
TRIAL (EMERALD)